Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis

Genes and Cancer

Volumn 1, Issue 11, 2010, Pages 1147-1156

  Gelman, Irwin H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cell motility; Cell cell barriers; Cyclin D; Cytokinesis; G1 S progression; Metastasis; Neovascularization; PKA; PKC; Prostate cancer; Ras; Src; SSeCKS Gravin AKAP12; Tumor invasiveness; VEGF

Indexed keywords

A KINASE ANCHORING PROTEIN 12; ACTIN; AKAP 12; AUTOANTIGEN; BETA 2 ADRENERGIC RECEPTOR; CALMODULIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLINE; GALACTOSYLTRANSFERASE; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; CANCER GROWTH; CANCER INHIBITION; CELL AGING; CELL PROLIFERATION; CYTOKINESIS; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PAIN RECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW;

EID: 79960046705     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910392984     Document Type: Review

References (116)

1. Ln X, Tombler E, Nelson PJ, Ross M, Gelman IH. A novel src-and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem. 1996;271:28, 430-28, 438.
2. Chapline C, Cottom J, Tobin H, Hulmes J, Crabb J, Jaken S. A major, transformation-sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling. J Biol Chem. 1998;273:19482-9.
3. Lin X, Gelman IH. Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res. 1997;57:2304-12.
4. Xia W, Gelman IH. Mitogen-and FAK-regulated tyrosine phosphorylation of the SSeCKS scaffolding protein modulates its actin-binding properties. Exp Cell Res. 2002;277:139-51.
5. Tao J, Wang HY, Malbon C. Src docks to AKAP Gravin, regulating beta-adrenergic receptor resensitization and recycling. J Biol Chem. 2007;282:6597-608.
6. Gordon T, Grove B, Loftus JC, et al. Molecular cloning and prelimnary characteriztion of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest. 1992;90:992-9.
7. Sasaki H, Kunimatsu M, Funii Y, et al. Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. Surgery Today. 2001;31:1036-7.
8. Lin X, Nelson P, Gelman IH. Regulation of G->S progression by the SSeCKS tumor suppressor: control of cyclin D expression and cellular compartmentalization. Mol Cell Biol. 2000;20: 7259-72.
9. Nelson PJ, Moissoglu K, Vargas JJ, Klotman PE, Gelman IH. Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. J Cell Sci. 1999;112:361-70.
10. Lin X, Nelson PJ, Frankfort B, Tombler E, Johnson R, Gelman IH. Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras. Mol Cell Biol. 1995;15:2754-62.
11. Nauert J, Klauck T, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffolding protein. Curr Biol. 1997;7:52-62.
12. Streb JW, Miano JM. Cross-species sequence analysis reveals multiple charged residue-rich domains that regulate nuclear/cytoplasmic partitioning and membrane localization of a kinase anchoring protein 12 (SSeCKS/Gravin). J Biol Chem. 2005;280:28007-14.
13. Yan X, Walkiewicz M, Carlson J, Leiphon L, Grove B. Gravin dynamics regulates the subcellular distribution of PKA. Exp Cell Res. 2009;315:1247-59.
14. Gelman IH. The role of the SSeCKS/Gravin/ AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci. 2002;7:d1782-97.
15. Lin X, Gelman IH. Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCKS. Biochem Biophys Res Commun. 2002;290:1368-75.
16. Caberoy NB, Zhou Y, Alvarado G, Fan X, Li W. Efficient identification of phosphatidylserinebinding proteins by ORF phage display. Biochem Biophys Res Commun. 2009;386:197-201.
17. Hyatt SL, Liao L, Aderem A, Nairn AC, Jaken S. Correlation between protein kinase C binding proteins and substrates in REF52 cells. Cell Growth Differ. 1994;5:495-502.
18. Wassler MJ, Foote CI, Gelman IH, Shur BD. Functional interaction between the SSeCKS scaffolding protein and the cytoplasmic domain of beta 1,4-galactosyltransferase. J Cell Sci. 2001;114:2291-300.
19. Gelman IH. Metastasis suppression by SSeCKS/ Gravin/AKAP12 through the spatiotemporal control of oncogenic signaling mediators. In: Maria-Magdalena Georgescu, editor. Adaptor proteins and cancer. Kerala, India: Transworld Research Network; 2008. p. 83-101.
20. Streb JW, Kitchen CM, Gelman IH, Miano JM. Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. J Biol Chem. 2004;279:56014-23.
21. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH. Loss of the SSeCKS/Gravin/ AKAP12 gene results in prostatic hyperplasia. Cancer Res. 2008;68:5096-103.
22. Weiser DC, Pyati UJ, Kimelman D. Gravin regulates mesodermal cell behavior changes required for axis elongation during zebrafish gastrulation. Genes Dev. 2007;21:1559-71.
23. Victor K, Jacob J, Cafiso DS. Interactions controlling the membrane binding of basic protein domains: phenylalanine and the attachment of the myristoylated alanine-rich C-kinase substrate protein to interfaces. Biochemistry. 1999; 38:12527-36.
24. Chapline C, Mousseau B, Ramsay K, et al. Identification of a major protein kinase C-binding protein and substrate in rat embryo fibroblasts: decreased expression in transformed cells. J Biol Chem. 1996;271:6417-22.
25. Weiser DC, Julien KR, Lang JS, Kimelman D. Cell shape regulation by Gravin requires Nterminal membrane effector domains. Biochem Biophys Res Commun. 2008;375:512-6.
26. Shih ML, Lin FB, Scott JD, Wang HY, Malbon CC. Dynamic complexes of ß(2)-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem. 1999;274:1588-95.
27. Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J. 2006;25:2051-61.
28. Nelson P, Gelman IH. Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with cell confluency, G0 phase and serum response. Molec Cell Biochem. 1997;175:233-41.
29. Tao J, Wang HY, Malbon CC. Src docks to A-kinase anchoring protein gravin, regulating beta2-adrenergic receptor resensitization and recycling. J Biol Chem. 2007;282:6597-608.
30. Tao J, Wang HY, Malbon CC. Protein kinase A regulates AKAP250 (gravin) scaffold binding to the beta2-adrenergic receptor. EMBO J. 2003;22:6419-29.
31. Tao J, Wang HY, Malbon C. AKAR2-AKAP12 fusion protein "biosenses" dynamic phosphorylation and localization of a GPCR-based scaffold. J Molec Signal. 2010;5:3.
32. Malbon CC, Tao JC, Wang HY. AKAPs (A-kinase anchoring proteins) and molecules that compose their G-protein-coupled receptor signalling complexes. Biochem J. 2004;379:1-9.
33. Piontek J, Brandt R. Differential and regulated binding of PKA and PKC isoenzymes to gravin in human model neurons: evidence that gravin provides a dynamic platform for the localization of kinases during neuronal development. J Biol Chem. 2003;278:38970-9.
34. Yan XH, Carlson J, Grove BD. Gravin targets PKA RII to the cell periphery in cultured cells. FASEB J. 2004;18:A784.
35. Martin LJ, Chen H, Liao X, et al. FK506, a calcineurin inhibitor, prevents cadmiuminduced testicular toxicity in mice. Toxicol Sci. 2007;100:474-85.
36. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 2001;61:5644-51.
37. Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest. 2004;51:146-53.
38. Rhim JH, Jang IS, Yeo EJ, Song KY, Park SC. Role of protein kinase C-dependent A-kinase anchoring proteins in lysophosphatidic acidinduced cAMP signaling in human diploid fibroblasts. Aging Cell. 2006;5:451-61.
39. Choi MC, Lee YU, Kim SH, et al. A-kinase anchoring protein 12 regulates the completion of cytokinesis. Biochem Biophys Res Commun. 2008;373:85-9.
40. Hutchins JRA, Toyoda Y, Hegemann B, et al. Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science. 2010;328:593-9.
41. Kittler R, Pelletier L, Heninger AK, et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol. 2007;9:1401-12.
42. Werner M, Glotzer M. Control of cortical contractility during cytokinesis. Biochem Soc Trans. 2008;36:371-7.
43. Gelman IH, Gao L. The SSeCKS/Gravin/ AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways. Molec Cancer Res. 2006;4:151-8.
44. Su B, Bu Y, Engelberg D, Gelman IH. SSeCKS/ Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a PKCRAF/ MEK/ERK pathway. J Biol Chem. 2010; 285:4578-86.
45. Busch H, Camacho-Trullio D, Rogon Z, et al. Gene network dynamics controlling keratinocyte migration. Mol Syst Biol. 2008;4:199.
46. Gelman IH, Lee K, Tombler E, Gordon R, Lin X. Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. Cell Motil Cytoskel. 1998;41:1-17.
47. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene. 2004;23:3737-48.
48. Schlosser I, Holzel M, Murnseer M, Burtscher H, Weidle UH, Eick D. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003;31:6148-56.
49. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Mycregulated gene expression patterns. J Biol Chem. 2003;278:12563-73.
50. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000;97:3260-5.
51. Cohen SB, Waha A, Gelman IH, Vogt PK. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. Oncogene. 2001;20: 141-6.
52. Yen A, Lin DM, Lamkin TJ, Varvayanis S. retinoic acid, bromodeoxyuridine, and the Delta 205 mutant polyoma virus middle T antigen regulate expression levels of a common ensemble of proteins associated with early stages of inducing HL-60 leukemic cell differentiation. In Vitro Cell Dev Biol Anim. 2004;40:216-41.
53. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989;49:3713-21.
54. Bu Y, Gelman IH. v-Src-mediated downregulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. J Biol Chem. 2007;282:26725-39.
55. Bu Y, Gao L, Gelman IH. Role for transcription factor TFII-I in the suppression of SSeCKS/ Gravin/Akap12 transcription by Src. Int J Cancer. Epub 2010 Jun 21.
56. Daoud SS, Munson PJ, Reinhold W, et al. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res. 2003;63:2782-93.
57. Lee SW, Kim WJ, Choi YK, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med. 2003;9:900-6.
58. Zhang X, Ma L, Enkemann SA, Pledger WJ. Role of Gadd45alpha in the density-dependent G1 arrest induced by p27(Kip1). Oncogene. 2003;22:4166-74.
59. Ali NA, McKay MJ, Molloy MP. Proteomics of Smad4 regulated transforming growth factorbeta signalling in colon cancer cells. Mol Bio- Syst. 2010;6:2332-8.
60. Yoo JY, Huso DL, Nathans D, Desiderio S. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell. 2002;108:331-44.
61. Palmer HG, Sanchez-Carbayo M, Ordonez- Moran P, Larriba MJ, Cordon-Cardo C, Munoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 2003;63:7799-806.
62. Kovalenko PL, Zhang Z, Cui M, Clinton SK, Fleet JC. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics. 2010;11:26.
63. Chen J, Maltby KM, Miano JM. A novel retinoid-response gene set in vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;281:475-82.
64. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem. 2005;280:14675-83.
65. Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem. 2003;278:52651-9.
66. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002;99:11890-5.
67. Shao C, Wang Y, Yue HH, et al. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl. 2007;28:804-12.
68. Singh AP, Bafna S, Chaudhary K, et al. Genomewide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 2008;259: 28-38.
69. Dydensborg AB, Rose AA, Wilson BJ, et al. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 2009;28:2634-42.
70. Choi MC, Jong HS, Kim TY, et al. AKAP12/ Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene. 2004;23: 7095-103.
71. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res. 2006;12:3882-9.
72. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with VEGF inhibition. Cancer Res. 2006;66:5599-607.
73. Wikman H, Kettunen E, Seppanen JK, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002;21:5804-13.
74. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig. 2003;10:161-71.
75. Boultwood J, Pellagatti A, Watkins F, et al. Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2004;126:508-11.
76. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756-64.
77. Yildirim M, Paydas S, Tanriverdi K, Seydaoglu G, Disel U, Yavuz S. Gravin gene expression in acute leukaemias: clinical importance and review of the literature. Leuk Lymphoma. 2007;48: 1167-72.
78. Heller G, Schmidt WM, Ziegler B, et al. Genome-wide transcriptional response to 5-aza- 2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008;68:44-54.
79. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003;9:68-75.
80. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-43.
81. Lim EH, Aggarwal A, Agasthian T, et al. Feasibility of using low-volume tissue samples for gene expression profiling of advanced non-small cell lung cancers. Clin Cancer Res. 2003;9: 5980-7.
82. Daino K, Ugolin N, Altmeyer-Morel S, Guilly MN, Chevillard S. Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiation-induced tumorigenesis of bone. Int J Cancer. 2009;125:612-20.
83. Daino K, Roch-Lefevre S, Ugolin N, Altmeyer- Morel S, Guilly MN, Chevillard S. Silencing of Cited2 and Akap12 genes in radiation-induced rat osteosarcomas. Biochem Biophys Res Commun. 2009;390:654-8.
84. Hacker E, Muller K, Whiteman DC, Pavey S, Hayward N, Walker G. Reduced expression of IL-18 is a marker of ultraviolet radiation-induced melanomas. Int J Cancer. 2008;123:227-31.
85. Bonazzi VF, Irwin D, Hayward NK. Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chrom Cancer. 2009;48:10-21.
86. Choi YK, Kim JH, Kim WJ, et al. AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor- 1alpha. J Neurosci. 2007;27:4472-81.
87. Feng XD, Huang SG, Shou JY, et al. Analysis of pathway activity in primary tumors and NCI60 cell lines using gene expression profiling data. Genom Proteom Bioinform. 2007;5:15-24.
88. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterol. 2006;131:797-808.
89. Yoon DK, Jeong CH, Jun HO, et al. AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett. 2007;254: 111-8.
90. Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004;149:98-106.
91. Yan B, Yang X, Lee TL, et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol. 2007;8:R78.
92. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-7.
93. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
94. Tonin PN, Hudson TJ, Rodier F, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617-26.
95. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-6.
96. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001;98:1176-81.
97. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-47.
98. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784-9.
99. Jo U, Whang YM, Kim HK, Kim YH. AKAP12alpha is associated with promoter methylation in lung cancer. Cancer Res Treat. 2009;38:144-51.
100. Tessema M, Willink R, Do K, et al. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res. 2008;68:1707-14.
101. Wang J, Qin R, Ma Y, et al. Differential gene expression in normal esophagus and Barrett's esophagus. J Gastroenterol. 2009;44:897-911.
102. Jin Z, Hamilton JP, Yang J, et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev. 2008;17:111-7.
103. Jin Z, Cheng Y, Gu W, et al. A multicenter, double- blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009;69:4112-5.
104. Zhu Y, Hollmen J, Raty R, et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol. 2002;119:905-15.
105. Yang J, Kiefer S, Rauchman M. Characterization of the gene encoding mouse retinoblastoma binding protein-7, a component of chromatin-remodeling complexes. Genomics. 2002;80:407-15.
106. Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem. 2005;280:27638-44.
107. Carinci F, Piattelli A, Martinelli M, et al. Genetic profiling of central giant cell granuloma of the jaws. J Craniofac Surg. 2005;16:399-407.
108. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997;57:5328-35.
109. Lahav R, Suva ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res. 2004;64:8945-53.
110. Choi YK, Kim KW. AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS J. 2008;275:2338-53.
111. You QH, Sun GY, Wang N, Shen JL, Wang Y. Interleukin-17F-induced pulmonary microvascular endothelial monolayer hyperpermeability via the protein kinase C pathway. J Surg Res. 2009;162:110-21.
112. You QH, Sun GY, Wang N, Chen S, Luo QL. Role of src-suppressed C kinase substrate in rat pulmonary microvascular endothelial hyperpermeability stimulated by inflammatory cytokines. Inflamm Res. 2010;59:949-58.
113. Malbon CC. A-kinase anchoring proteins: trafficking in G-protein-coupled receptors and the proteins that regulate receptor biology. Curr Opin Drug Discov Devel. 2007;10: 573-9.
114. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167:223-9.
115. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-58.
116. Mardin WA, Petrov KO, Enns A, Senninger N, Haier J, Mees ST. SERPINB5 and AKAP12: expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma. BMC Cancer. 2010;10:549.